Kiniksa Pharmaceuticals International, plc (KNSA)

Every figure this model derived for KNSA, the value it took, and the element in the company's own XBRL it was read from — so any of it can be checked against the filing rather than taken on trust. As at 2026-03-31.

The figures, and where each came from

This is the part no other screener shows. Each figure below names the XBRL element it was read from, so it can be checked against the filing itself.

FigureValueXBRL tagAs at
capex 1,630,000 PaymentsToAcquirePropertyPlantAndEquipment 2026-03-31
cash 468,093,000 CashAndCashEquivalentsAtCarryingValue 2026-03-31
current assets 594,172,000 AssetsCurrent 2026-03-31
current liabilities 156,611,000 LiabilitiesCurrent 2026-03-31
equity 605,687,000 StockholdersEquity 2026-03-31
ocf 165,860,000 NetCashProvidedByUsedInOperatingActivities 2026-03-31
revenue 754,045,000 RevenueFromContractWithCustomerExcludingAssessedTax 2026-03-31
sbc 39,311,000 ShareBasedCompensation 2026-03-31

The ratios

The figures themselves rather than their scores — what somebody looking up KNSA on one particular measure came for.

RatioValue
cash operating margin17.8
current ratio3.79
current ratio reported3.79
deferred revenue growth-99.74
dilution pct10.59
ebit cagr100.28
fcf margin21.78
growth cv1.21
operating margin12.36
owner earnings margin16.57
revenue growth56.71
revenue growth per share41.71
roic53.52
rule of 4069.07
sbc pct revenue5.21

What to be careful about

What this model itself distrusts about KNSA's figures. Written by the derivation as it ran, not added afterwards.